C4 Therapeutics (CCCC) Non Operating Investment Income (2020 - 2025)
C4 Therapeutics' quarterly Non Operating Investment Income came in at -$73000.0 in Q2 2025, down 21.67% year-on-year from -$93191.5 in Q2 2024, and down 630.0% quarter-over-quarter from -$10000.0 in Q1 2025.
C4 Therapeutics has reported Non Operating Investment Income for 6 years, with the latest figure at -$73000.0 in Q2 2025.
- For the quarter ending Q2 2025, Non Operating Investment Income fell 21.67% year-over-year to -$73000.0; the trailing twelve-month figure through Jun 2025 stood at $410000.0 (down 69.27% YoY), and the FY2025 full-year result was -$3000.0, down 101.67% from the prior year.
- Non Operating Investment Income for Q2 2025 stood at -$73000.0, down from -$10000.0 in the prior quarter.
- The five-year high for Non Operating Investment Income was $1.7 million in Q1 2023, with the low at -$2.9 million in Q1 2022.
- Average Non Operating Investment Income over 5 years is -$2388.9, with a median of -$66500.0 recorded in 2024.
- Peak annual rise in Non Operating Investment Income reached 1350.0% in 2021, while the deepest fall reached 12500.0% in 2021.
- Tracing CCCC's Non Operating Investment Income over 5 years: stood at -$620000.0 in 2021, then soared by 305.16% to $1.3 million in 2022, then slumped by 38.92% to $777000.0 in 2023, then sank by 151.74% to -$402000.0 in 2024, then jumped by 81.84% to -$73000.0 in 2025.
- The last three Non Operating Investment Income figures came in at -$73000.0 (Q2 2025), -$10000.0 (Q1 2025), and -$402000.0 (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 235,807.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 230,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | C4 Therapeutics | 561.03 Mn | 325.36 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -73,000.00 |
| Jun 30, 2025 | -73,000.00 |
| Mar 31, 2025 | -10,000.00 |
| Mar 31, 2025 | -10,000.00 |
| Dec 31, 2024 | -402,000.00 |
| Dec 31, 2024 | -402,000.00 |
| Sep 30, 2024 | 895,000.00 |
| Sep 30, 2024 | 895,000.00 |
| Jun 30, 2024 | -60,000.00 |
| Jun 30, 2024 | -60,000.00 |
| Mar 31, 2024 | -253,000.00 |
| Mar 31, 2024 | -253,000.00 |
| Dec 31, 2023 | 777,000.00 |
| Dec 31, 2023 | 777,000.00 |
| Sep 30, 2023 | 870,000.00 |
| Sep 30, 2023 | 870,000.00 |
| Jun 30, 2023 | 696,000.00 |
| Jun 30, 2023 | 696,000.00 |
| Mar 31, 2023 | 1.67 Mn |
| Mar 31, 2023 | 1.67 Mn |
| Dec 31, 2022 | 1.27 Mn |
| Dec 31, 2022 | 1.27 Mn |
| Sep 30, 2022 | -828,000.00 |
| Sep 30, 2022 | -828,000.00 |
| Jun 30, 2022 | -931,000.00 |
| Jun 30, 2022 | -931,000.00 |
| Mar 31, 2022 | -2.88 Mn |
| Mar 31, 2022 | -2.88 Mn |
| Dec 31, 2021 | -620,000.00 |
| Dec 31, 2021 | -620,000.00 |
| Sep 30, 2021 | -86,000.00 |
| Sep 30, 2021 | -86,000.00 |
| Jun 30, 2021 | 25,000.00 |
| Jun 30, 2021 | 25,000.00 |
| Mar 31, 2021 | -107,000.00 |
| Mar 31, 2021 | -107,000.00 |
| Dec 31, 2020 | 5,000.00 |
| Dec 31, 2020 | 5,000.00 |
| Sep 30, 2020 | 10,000.00 |
| Sep 30, 2020 | 10,000.00 |
| Jun 30, 2020 | -2,000.00 |
| Jun 30, 2020 | -2,000.00 |